Abstract
Introduction: Patients requiring major cardiovascular surgery are likely to be prescribed antiplatelet agents either alone or in combination. By virtue of antiplatelet agent effect, they can potentially increase bleeding complications, especially if used in combination. This article aims to review the evidence and make appropriate recommendations regarding these agents. Aspirin: 16 papers are reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is from the coronary bypass setting. Clopidogrel: 14 papers are reviewed which concern surgery whilst taking clopidogrel. Dipyridamole: 2 papers are reviewed concerning dipyridamole. Cilostazol: No trials are available concerning surgery and cilostazol. Several relevant publications are reviewed. Conclusion: It is the recommendation of the authors that aspirin should usually be continued perioperatively, whilst clopidogrel should be stopped for seven days prior to surgery if at all possible.
Keywords: Aspirin, platelet aggregation inhibitors, cardiac surgical procedures, vascular surgical procedures, haemorrhage, post-operative complications
Current Drug Safety
Title: Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery
Volume: 1 Issue: 3
Author(s): James McCaslin, Jonathan Smout, Patrick Kesteven and Gerard Stansby
Affiliation:
Keywords: Aspirin, platelet aggregation inhibitors, cardiac surgical procedures, vascular surgical procedures, haemorrhage, post-operative complications
Abstract: Introduction: Patients requiring major cardiovascular surgery are likely to be prescribed antiplatelet agents either alone or in combination. By virtue of antiplatelet agent effect, they can potentially increase bleeding complications, especially if used in combination. This article aims to review the evidence and make appropriate recommendations regarding these agents. Aspirin: 16 papers are reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is from the coronary bypass setting. Clopidogrel: 14 papers are reviewed which concern surgery whilst taking clopidogrel. Dipyridamole: 2 papers are reviewed concerning dipyridamole. Cilostazol: No trials are available concerning surgery and cilostazol. Several relevant publications are reviewed. Conclusion: It is the recommendation of the authors that aspirin should usually be continued perioperatively, whilst clopidogrel should be stopped for seven days prior to surgery if at all possible.
Export Options
About this article
Cite this article as:
McCaslin James, Smout Jonathan, Kesteven Patrick and Stansby Gerard, Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934486
DOI https://dx.doi.org/10.2174/157488606777934486 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology Application of In-Line Liquid Chromatography-Accurate Radioisotope Counting-Mass Spectrometry (LC-ARC-MS) to Evaluate Metabolic Profile of [3H]-Mefenamic Acid in Rat Plasma
Drug Metabolism Letters Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Single Cell Sequencing Coming of Edge
Current Genomics Cardiovascular Therapeutics Targets on the NO–sGC–cGMP Signaling Pathway: A Critical Overview
Current Drug Targets Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Pulmonary Hypertension Related to Left Heart Disease (PH-LHD)
Current Respiratory Medicine Reviews Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Molecular Manipulation of G Protein coupled Receptors A New Avenue into Drug Discovery
Current Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology PPARα/HNF4α Interplay on Diversified Responsive Elements. Relevance in the Regulation of Liver Peroxisomal Fatty Acid Catabolism
Current Drug Metabolism Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Putative Role for Apelin in Pressure/Volume Homeostasis and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science